127 related articles for article (PubMed ID: 23930209)
1. Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma.
Werner D; Atmaca A; Pauligk C; Pustowka A; Jäger E; Al-Batran SE
Cancer Med; 2013 Jun; 2(3):325-33. PubMed ID: 23930209
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma.
Chung V; Frankel P; Lim D; Yeon C; Leong L; Chao J; Ruel N; Luevanos E; Koehler S; Chung S; Lau SC; Fakih MG
Oncology; 2016; 90(6):307-12. PubMed ID: 27093189
[TBL] [Abstract][Full Text] [Related]
3. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
4. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.
Lim T; Lee J; Lee DJ; Lee HY; Han B; Baek KK; Ahn HK; Lee SJ; Park SH; Park JO; Park YS; Lim HY; Kim KM; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):255-62. PubMed ID: 21526353
[TBL] [Abstract][Full Text] [Related]
7. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
[TBL] [Abstract][Full Text] [Related]
8. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Chinnaiyan P; Won M; Wen PY; Rojiani AM; Wendland M; Dipetrillo TA; Corn BW; Mehta MP
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):880-4. PubMed ID: 23725999
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
Pant S; Patel M; Kurkjian C; Hemphill B; Flores M; Thompson D; Bendell J
Cancer Invest; 2017 Aug; 35(7):463-472. PubMed ID: 28662341
[TBL] [Abstract][Full Text] [Related]
10. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
Lustberg MB; Bekaii-Saab T; Young D; Otterson G; Burak W; Abbas A; McCracken-Bussa B; Lustberg ME; Villalona-Calero MA
J Thorac Oncol; 2010 May; 5(5):713-8. PubMed ID: 20354452
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
12. Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study.
Shah MA; Starodub A; Sharma S; Berlin J; Patel M; Wainberg ZA; Chaves J; Gordon M; Windsor K; Brachmann CB; Huang X; Vosganian G; Maltzman JD; Smith V; Silverman JA; Lenz HJ; Bendell JC
Clin Cancer Res; 2018 Aug; 24(16):3829-3837. PubMed ID: 29691300
[No Abstract] [Full Text] [Related]
13. Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
Giuliani F; Molica S; Maiello E; Battaglia C; Gebbia V; Di Bisceglie M; Vinciarelli G; Gebbia N; Colucci G;
Am J Clin Oncol; 2005 Dec; 28(6):581-5. PubMed ID: 16317268
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.
Jatoi A; Tirona MT; Cha SS; Alberts SR; Rowland KM; Morton RF; Nair S; Kardinal CG; Stella PJ; Mailliard JA; Sargen D; Goldberg RM
Int J Gastrointest Cancer; 2002; 32(2-3):115-23. PubMed ID: 12794247
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
Pinto C; Di Fabio F; Siena S; Cascinu S; Rojas Llimpe FL; Ceccarelli C; Mutri V; Giannetta L; Giaquinta S; Funaioli C; Berardi R; Longobardi C; Piana E; Martoni AA
Ann Oncol; 2007 Mar; 18(3):510-7. PubMed ID: 17164226
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
Lorenzen S; Knorrenschild JR; Pauligk C; Hegewisch-Becker S; Seraphin J; Thuss-Patience P; Kopp HG; Dechow T; Vogel A; Luley KB; Pink D; Stahl M; Kullmann F; Hebart H; Siveke J; Egger M; Homann N; Probst S; Goetze TO; Al-Batran SE
Int J Cancer; 2020 Nov; 147(9):2493-2502. PubMed ID: 32339253
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
Gastric Cancer; 2019 Jul; 22(4):817-827. PubMed ID: 30515672
[TBL] [Abstract][Full Text] [Related]
19. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
20. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Catenacci DVT; Kang YK; Park H; Uronis HE; Lee KW; Ng MCH; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS; Oh SC; Kim YH; Marrone KA; Kelly RJ; Juergens RA; Kim JG; Bendell JC; Alcindor T; Sym SJ; Song EK; Chee CE; Chao Y; Kim S; Lockhart AC; Knutson KL; Yen J; Franovic A; Nordstrom JL; Li D; Wigginton J; Davidson-Moncada JK; Rosales MK; Bang YJ;
Lancet Oncol; 2020 Aug; 21(8):1066-1076. PubMed ID: 32653053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
